These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Long-term results and risk factors of quadruple immunosuppression in renal transplantation. Hiesse C, Kriaa F, Eschwege P, Boubenider S, Marchand S, Benoit G, Charpentier B. Transplant Proc; 1999 Feb; 31(1-2):1111-2. PubMed ID: 10083496 [No Abstract] [Full Text] [Related]
23. Comparison of OKT3 and antithymocyte globulin as induction immunosuppressive agents in renal transplantation. Kitabayashi K, Munn SR, Sterioff S. Transplant Proc; 1996 Jun; 28(3):1973-5. PubMed ID: 8658964 [No Abstract] [Full Text] [Related]
24. Prophylactic OKT3 monoclonal antibody versus antilymphocyte globulins: a prospective, randomized study in 148 first cadaver kidney grafts. Broyer M, Gagnadoux MF, Guest G, Arsan A, Beurton D, Revillon Y, Niaudet P. Transplant Proc; 1993 Feb; 25(1 Pt 1):570-1. PubMed ID: 8438418 [No Abstract] [Full Text] [Related]
25. Delayed graft function adversely affects one-year graft survival of cadaveric renal transplants. Carmellini M, Stefano RD, Filipponi F, Rindi P, Rizzo G, Mosca F. Transplant Proc; 1996 Feb; 28(1):359-60. PubMed ID: 8644262 [No Abstract] [Full Text] [Related]
26. Improved cadaveric kidney graft survival with initiation of antilymphocyte globulin pretransplant in patients with a positive flow cytometry crossmatch. Hong JH, Sadeghian M, Sumrani N, Cacciarelli TV, Distant DA, Sommer BG, Norin AJ. Transplant Proc; 1996 Jun; 28(3):1340-1. PubMed ID: 8658685 [No Abstract] [Full Text] [Related]
27. Delayed graft function is associated with an increased incidence of occult rejection and results in poorer graft survival. Howard RJ, Pfaff WW, Brunson ME, Ramos EL, Peterson JC, Croker BP, Scornik JC, Parris CJ, Fennell RS. Transplant Proc; 1993 Feb; 25(1 Pt 2):884. PubMed ID: 8442256 [No Abstract] [Full Text] [Related]
29. Single-center analysis of 468 first cadaveric kidney allografts with a uniform ATG-CsA sequential therapy. Giral M, Taddei C, Nguyen JM, Dantal J, Hourmant M, Cantarovich D, Blancho G, Ancelet D, Soulillou JP. Clin Transpl; 1996 Jun; ():257-64. PubMed ID: 9286575 [Abstract] [Full Text] [Related]
30. Accelerated acute rejection in renal allograft. Han DJ, Yoon HS, Lee HM. Transplant Proc; 1996 Jun; 28(3):1455. PubMed ID: 8658738 [No Abstract] [Full Text] [Related]
31. Impact of HLA matching, type of crossmatch, and immunosuppressive therapy on primary pediatric cadaver renal allograft survival. Kerman RH, Sullivan EK, Tejani A. Transplant Proc; 1995 Feb; 27(1):656-7. PubMed ID: 7879133 [No Abstract] [Full Text] [Related]
32. Prospective randomised study of the influence of cyclosporin on long-term renal allograft function. Rowe PA, Watson MA, McMillan MA, Briggs JD, Rodger RS, Junor BJ. Transplant Proc; 1994 Oct; 26(5):2617-8. PubMed ID: 7940814 [No Abstract] [Full Text] [Related]
33. Long-term results of a prospective randomized study comparing two immunosuppressive regimens, one with and one without CsA, in low-risk renal transplant recipients. Grimbert P, Baron C, Fruchaud G, Hemery F, Desvaux D, Buisson C, Chopin D, Dahmane D, Remy P, Pastural M, Abbou C, Weil B, Lang P. Transpl Int; 2002 Nov; 15(11):550-5. PubMed ID: 12461659 [Abstract] [Full Text] [Related]
34. Beneficial effect of concomitant induction with antilymphoblast globulin, cyclosporine, and steroids on long-term renal allograft outcome. Koga A, Moreso FJ, Seron D, Gil-Vernet S, Cruzado JM, Castelao AM, Grinyó JM. Transplant Proc; 2004 Jun; 36(5):1305-7. PubMed ID: 15251318 [Abstract] [Full Text] [Related]
35. Early or delayed use of cyclosporine in HLA-mismatched living-related donor renal transplants. Sumrani N, Hong JH, Daskalakis P, Cacciarelli TV, Markell MS, Sommer BG. Transplant Proc; 1993 Jun; 25(3):2246-7. PubMed ID: 8516888 [No Abstract] [Full Text] [Related]
36. Outcome of monoclonal antibody induction and anti-rejection therapy in pancreas transplantation. Bruce DS, Newell KA, Woodle ES, Millis JM, Piper JB, Huss E, Thistlethwaite JR. Transplant Proc; 1996 Aug; 28(4):2136-7. PubMed ID: 8769180 [No Abstract] [Full Text] [Related]
37. Ten years of cyclosporine use in renal transplantation: a single-center experience with 479 renal transplants. Lucan M, Iacob G, Lucan C, Lăpuşan C, Munteanu A, Sîrbu S. Transplant Proc; 2004 Mar; 36(2 Suppl):177S-180S. PubMed ID: 15041332 [Abstract] [Full Text] [Related]
38. Posttransplant serum creatinine area under the curve predicts renal allograft outcome. Sumrani N, Hong J, Miles A, Markell M, Distant D, Fleishhacker J, Maursky V, Jean-Baptiste F, Sommer B. Transplant Proc; 1996 Feb; 28(1):356-7. PubMed ID: 8644260 [No Abstract] [Full Text] [Related]
39. Reduction of immunosuppressive therapy after renal transplantation: a randomized study. Heering P, Westhoff A, Ivens K, Kutkuhn B, Grabensee B. Transplant Proc; 1994 Oct; 26(5):2530-2. PubMed ID: 7940778 [No Abstract] [Full Text] [Related]
40. Chronic renal allograft function under cyclosporin treatment. Leuven Collaborative Group for Transplantation. Vanrenterghem Y, Peeters J. Transplant Proc; 1996 Aug; 28(4):2097-9. PubMed ID: 8769165 [No Abstract] [Full Text] [Related] Page: [Previous] [Next] [New Search]